Abstract
Recent evidence from our laboratories and from others has suggested the ability of monoclonal antibodies (MAb) against a human B lymphocyte alloantigen to discriminate between RF/RHD susceptible individuals and persons with a lower risk of developing RF. However, while such MAb can identify a majority of RF/RHD patients in some populations, reduced discriminatory ability has been observed in other groups. Antigenic variation in the marker(s) may exist among ethnic groups which can adversely influence the specificity of the test. To examine this possibility, we developed MAb made from B lymphocytes of North Indian ethnic origin. In the same population we compared a new MAb (PGI/MN II) with a previously described MAb of Caucasian ethnic origin (D8/17). The results indicate significantly (p<0.0001) greater discriminating ability of this new MAb for patients with RF/RHD in the North Indian population and support our hypothesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
